The IMID Forum
431 episodes — Page 6 of 9

Author Interview: Professor Atul Deodhar
Professor Atul Deodhar, professor of medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Atul Deodhar discusses his review on JAK-STAT signalling in spondyloarthritis and what that means for the use of JAK inhibitors for SpA treatment.

Discussing Rheumatology: Risk of HZ with UPA, and JAKs in SpA
Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Author Interview: Professor Roy Fleischmann
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.

ACR 2021: Day 4 Highlights
Grace Wright presents the Day 4 highlights of the key abstracts and posters presented at ACR 2021.

ACR 2021: Day 3 Highlights
Professor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.

ACR 2021: Day 2 Highlights
Grace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.

Discussing Rheumatology: Herpes Zoster and HBV
Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

ACR 2021: Day 1 Highlights
Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.

ACR 2021 Preview Podcast
A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.

Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness
Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy
Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Rheumatology Author Professor Kurt de Vlam: Pain Improvements
Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.

Rheumatology Author Professor Strand: Upadacitinib and PROs
Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.

Discussing Rheumatology: Patient Reported Outcomes
Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Discussing Rheumatology: SELECT-PsA 2 and DMARDs in COVID-19
Prof Iain McInnes discusses long-term data from the SELECT-PsA 2 study, and the impact of DMARDs on COVID-19 outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Rheumatology Author Professor Mease: Upadacitinib
Philip Mease, Professor at the University of Washington School of Medicine in Seattle. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Mease discusses the longer-term safety and maintenance of efficacy of upadacitinib in patients with RA.

Rheumatology Authors Jeffrey Sparks and Zachary Wallace
Jeffrey Sparks, from Brigham and Women's Hospital in Boston, and Zachary Wallace from the Massachusetts General Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Jeffery Sparks and Zachary Wallace discuss the latest results from the COVID-19 Global Rheumatology Alliance physician registry.

Rheumatology Author Professor Francesco Ciccia: JAKis and Pain
Francesco Ciccia, Assistant Professor of Rheumatology at the University of Palermo in Italy. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Ciccia discusses with Professor Nash the impact of pain in patients with rheumatic diseases and the physiological basis of modulating nociceptive pain, speculating that JAK inhibitors may have a dual therapeutic role.

Discussing Rheumatology: 2021 EULAR Highlights
Prof Iain McInnes discusses the main highlights of EULAR 2021 and the key takeaway messages. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Rheumatology Author Professor Stanley Cohen: Radiographic Progression
Stanley Cohen, Clinical Professor in the Department of Internal Medicine and Co-Director of the Division of Rheumatology from the UT Southwestern Medical Center and Presbyterian Hospital, Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Cohen discusses radiographic progression in patients with RA treated with tofacitinib.

Insights at EULAR 2021: Day 4 Highlights
Dr Elena Nikiphorou presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2021.

Insights at EULAR 2021: Day 3 Highlights
Professor Douglas Veale presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2021.

Insights at EULAR 2021: Day 2 Highlights
Dr Elena Nikiphorou presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2021.

Insights at EULAR 2021: Day 1 Highlights
Prof Veale presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2021.

Insights at EULAR 2021: Preview
A preview of the latest research at EULAR 2021. Prof Edwards presents a preview of the upcoming EULAR 2021 congress, highlighting important abstracts and posters in cytokine signalling.

Discussing Rheumatology: PsA and Radiographic Progression
Prof Iain McInnes discusses upadacitinib in PsA, and radiographic progression with tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Rheumatology Author Professor Yoshiya Tanaka: Filgotinib
Yoshiya Tanaka, Professor and Chairman of the department of Internal Medicine at the University of Occupational and Environmental Health in Kitakyushu, Japan. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tanaka discusses the safety and efficacy of filgotinib as a Novel JAK1-Preferential Inhibitor for the Treatment of RA.

Rheumatology Author Dr Rishi Desai: VTE
Dr Rishi Desai, is an Assistant Professor of Medicine at Harvard Medical School and an Associate Epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Rishi Desai discusses Risk of venous thromboembolism associated with tofacitinib in patients with RA

Discussing Rheumatology: JAKi and VTE
Prof Iain McInnes discusses JAKi and thromboembolism Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Rheumatology Author Dr Ben Nowell: ArthritisPower
Dr Ben Nowell, Director of Patient-Centred Research at CreakyJoints, part of the Global Healthy Living Foundation. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Ben Nowell a real-world longitudinal study in ArthritisPower

Discussing Rheumatology: Bone and PRO
Prof Iain McInnes discusses bone metabolism and PRO Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Rheumatology Author Professor Paul Emery: Baricitinib
Professor Paul Emery, an arthritis Research UK Professor of Rheumatology, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust, UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Paul discusses how baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis

Forum LIVE: Managing Patients During COVID
Professor Leonard Calabrese offers the latest advice on managing rheumatic patients during the pandemic and Professor Kimme Hyrich discusses the learnings from the COVID-19 Global Rheumatology Alliance registries, a year on from their inception.

Rheumatology Author Professor Lee Simon: Pain in RA
Dr Lee Simon, Principal Scientist in SDG LLG, Cambridge, US. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Lee Simon discusses pain in RA

Rheumatology Author Professor Tsutomu Takeuchi: Upadacitinib
Professor Tsutomu Takeuchi, HVice-President at Keio University and Professor of Medicine in the Division of Rheumatology and Clinical Immunology at Keio University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tsutomu Takeuchi discusses how upadacitinib monotherapy vs methotrexate monotherapy in methotrexate-naïve Japanese patients with RA

Rheumatology Author Prof René Westhovens: Filgotinib
Professor René Westhovens, Emeritus Prof of Rheumatology at the KU Leuven Belgium and a >30 year track in clinical research in Rheumatoid Arthritis. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor René Westhovens discusses his latest paper on use of filgotinib in combination with methotrexate or as filgotinib monotherapy versus methotrexate monotherapy in patients with active RA.

Discussing Rheumatology: February 2021 Podcast
Prof Iain McInnes discusses papers on filgotinib and the involvement of pain in RA. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Perspectives in Inflammation - Dr Grace Wright
Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace C Wright discusses her careeer and the future of AWIR. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world-leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Rheumatology Author Prof György Nagy: EULAR
Professor György Nagy from the Semmelweis University, Hungry. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor György Nagy discusses his latest paper on EULAR definition of difficult-to-treat RA

Rheumatology Author Prof Philip Mease: Upadacitinib in PsA
Professor Philip Mease from the University of Washington School of Medicine. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor Philip Mease discusses his latest paper on Upadacitinib for Psoriatic Arthritis refractory to biologics.

Discussing Rheumatology: JAKi and TNFi
Prof Iain McInnes discusses JAK inhibitors and TNFi in RA treatment. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Perspectives In Inflammation - Professor Weinblatt
In this podcast the Past President of ACR, Professor Michael Weinblatt discusses his involvement in the development of methotrexate and the expansion of his unit at the Brigham, alongside Professor Paul Emery. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Rheumatology Author Prof Josef Smolen: Barcitinib
Prof Josef Smolen from Medical University of Vienna. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Josef Smolen discusses efficacy of baricitinib in patients with RA

Rheumatology Author Dr Kerschbaumer: JAKinibs
Dr Andreas Kerschbaumer from Vienna University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Andreas Kerschbaumer discusses his systematic review paper on “Points to Consider for the Treatment of Immune Mediated Inflammatory Diseases with Janus Kinase Inhibitors

Rheumatology Author Roy Fleischmann: Switching Between UPA and ADA
Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.
Rheumatology Author Prof Kevin Winthrop: Tofacitinib
Prof Kevin Winthrop from OHSU. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Kevin Winthrop discusses aged based incidence of infections with tofacitinib

Discussing Rheumatology: JAK Inhibitors
Prof Iain McInnes discusses JAK inhibitors. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Perspectives in Inflammation - Professor Emery
Past President of EULAR and Carol Nachman Prize winner. In this podcast, Professor Paul Emery discusses his work in managing early RA and the growth of his unit at Leeds into a world leading centre for rheumatology research alongside Professor Michael Weinblatt. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.

Insights at ACR 2020: Highlights from ACR 2020
Gain insight into the latest research presented at ACR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes a preview of an upcoming Highlights from ACR 2020 course from Professors Kevin Winthrop and Leonard Calabrese, available soon on the CSF website.

Rheumatology Author Prof Stanley Cohen: Upadacitinib
Prof Stanley Cohen - University of Texas. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Stanley Cohen discusses safety profile of upadacitinib